Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARA 290 in Sarcoidosis Neuropathy
NCT02039687Phase 2Completed
- Sponsor
- Araim Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of cibinetide in sarcoidosis and small fiber neuropathy (SFN) (4 arms), sponsored by Araim Pharmaceuticals. Primary endpoint: Change in Corneal Nerve Fiber Area at 28 days. Started Jan 2014; status: completed.
02
Drugs
cibinetide
03
Conditions
sarcoidosissmall fiber neuropathy (SFN)
Beyond the preview
Go deeper on NCT02039687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039687.